Progenics asserts ownership of PSMA-617 IP, including composition of matter patent
Progenics Pharmaceuticals announced that it has asserted ownership of worldwide composition of matter patent filings related to PSMA-617, a PSMA targeted radiopharmaceutical compound under development by Novartis for the treatment of prostate cancer. March 14, 2019